Sight Sciences Overview
- Year Founded
-
2010

- Status
-
Public
- Employees
-
214

- Stock Symbol
-
SGHT

- Share Price
-
$2.71
- (As of Thursday Closing)
Sight Sciences General Information
Description
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Contact Information
Website
www.sightsciences.comCorporate Office
- 4040 Campbell Avenue
- Suite 100
- Menlo Park, CA 94025
- United States
Corporate Office
- 4040 Campbell Avenue
- Suite 100
- Menlo Park, CA 94025
- United States
Sight Sciences Stock Performance
As of 06-Feb-2025, Sight Sciences’s stock price is $2.71. Its current market cap is $137M with 50.4M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.71 | $2.87 | $2.67 - $8.45 | $137M | 50.4M | 230K | -$1.01 |
Sight Sciences Financials Summary
As of 30-Sep-2024, Sight Sciences has a trailing 12-month revenue of $79.5M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 233,784 | 141,723 | 422,445 | 593,867 |
Revenue | 79,543 | 81,056 | 71,331 | 48,956 |
EBITDA | (44,597) | (49,415) | (81,019) | (57,774) |
Net Income | (50,352) | (55,547) | (86,242) | (62,960) |
Total Assets | 143,597 | 166,651 | 213,073 | 280,186 |
Total Debt | 35,285 | 35,414 | 34,981 | 34,206 |
Sight Sciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Sight Sciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Sight Sciences Comparisons
Industry
Financing
Details
Sight Sciences Competitors (10)
One of Sight Sciences’s 10 competitors is Glaukos, a Formerly VC-backed company based in Aliso Viejo, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Glaukos | Formerly VC-backed | Aliso Viejo, CA | ||||
Nova Eye Medical | Corporation | Kent Town, Australia | ||||
MicroSurgical Technology | Corporate Backed or Acquired | Redmond, WA | ||||
Alcon | Corporate Backed or Acquired | Geneva, Switzerland | ||||
New World Medical | Corporation | Rancho Cucamonga, CA |
Sight Sciences Patents
Sight Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-12213914-B2 | Ocular delivery systems and methods | Active | 30-Nov-2023 | ||
US-20240173251-A1 | Bio-erodible ocular implants for treatment of conditions of the eye | Pending | 28-Nov-2022 | ||
US-20240225894-A1 | Ocular delivery systems and methods | Pending | 23-Aug-2022 | ||
US-20230293347-A1 | Devices and methods for intraocular tissue manipulation | Pending | 16-Mar-2022 | ||
US-20230293346-A1 | Devices and methods for intraocular tissue manipulation | Active | 16-Mar-2022 | A61F9/00772 |
Sight Sciences Signals
Sight Sciences Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Sight Sciences ESG
Risk Overview
Risk Rating
Updated September, 01, 2023
30.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Healthcare
Industry
of 587
Rank
Percentile

Medical Devices
Subindustry
of 199
Rank
Percentile

Sight Sciences FAQs
-
When was Sight Sciences founded?
Sight Sciences was founded in 2010.
-
Where is Sight Sciences headquartered?
Sight Sciences is headquartered in Menlo Park, CA.
-
What is the size of Sight Sciences?
Sight Sciences has 214 total employees.
-
What industry is Sight Sciences in?
Sight Sciences’s primary industry is Surgical Devices.
-
Is Sight Sciences a private or public company?
Sight Sciences is a Public company.
-
What is Sight Sciences’s stock symbol?
The ticker symbol for Sight Sciences is SGHT.
-
What is the current stock price of Sight Sciences?
As of 06-Feb-2025 the stock price of Sight Sciences is $2.71.
-
What is the current market cap of Sight Sciences?
The current market capitalization of Sight Sciences is $137M.
-
What is Sight Sciences’s current revenue?
The trailing twelve month revenue for Sight Sciences is $79.5M.
-
Who are Sight Sciences’s competitors?
Glaukos, Nova Eye Medical, MicroSurgical Technology, Alcon, and New World Medical are some of the 10 competitors of Sight Sciences.
-
What is Sight Sciences’s annual earnings per share (EPS)?
Sight Sciences’s EPS for 12 months was -$1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »